WO2002019894A3 - Methods for analyzing and using data from hypertensive patients - Google Patents

Methods for analyzing and using data from hypertensive patients Download PDF

Info

Publication number
WO2002019894A3
WO2002019894A3 PCT/US2001/028009 US0128009W WO0219894A3 WO 2002019894 A3 WO2002019894 A3 WO 2002019894A3 US 0128009 W US0128009 W US 0128009W WO 0219894 A3 WO0219894 A3 WO 0219894A3
Authority
WO
WIPO (PCT)
Prior art keywords
laragh
hypertensive
blood pressure
hypertensive patients
drug
Prior art date
Application number
PCT/US2001/028009
Other languages
French (fr)
Other versions
WO2002019894A2 (en
Inventor
John H Laragh
Original Assignee
John H Laragh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/657,027 external-priority patent/US6632180B1/en
Application filed by John H Laragh filed Critical John H Laragh
Priority to EP01968624A priority Critical patent/EP1322220A4/en
Priority to AU2001288861A priority patent/AU2001288861B2/en
Priority to CA002421285A priority patent/CA2421285A1/en
Priority to AU8886101A priority patent/AU8886101A/en
Priority to JP2002524383A priority patent/JP2004508546A/en
Publication of WO2002019894A2 publication Critical patent/WO2002019894A2/en
Publication of WO2002019894A3 publication Critical patent/WO2002019894A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The Laragh Method is a novel method useful for evaluating and treating hypertensive patients. The Laragh Method provides a systematic approach of the physician to use volume vascoconstriction information with entry and induced changes in blood pressure and in ambulatory plasma renin levels for the rational selection of treatment tailored to suit each individual hypertensive patient. The Laragh Method provides a systematic and rational approach to drug selection which greatly improves the therapeutic success rate among hypertensive patients and which for the large majority provides long-term blood pressure control with one drug instead of two or two instead of three with each drug rationally targeted to control the renin and/or volume elements in the blood pressure equation. The Laragh Method also may be used to evaluate and treat hypertensive crises. In addition, the Laragh Method may be used to analyze data from hypertensive patients.
PCT/US2001/028009 2000-09-07 2001-09-07 Methods for analyzing and using data from hypertensive patients WO2002019894A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01968624A EP1322220A4 (en) 2000-09-07 2001-09-07 Methods for analyzing and using data from hypertensive patients
AU2001288861A AU2001288861B2 (en) 2000-09-07 2001-09-07 Methods for analyzing and using data from hypertensive patients
CA002421285A CA2421285A1 (en) 2000-09-07 2001-09-07 Methods for analyzing and using data from hypertensive patients
AU8886101A AU8886101A (en) 2000-09-07 2001-09-07 Methods for analyzing and using data from hypertensive patients
JP2002524383A JP2004508546A (en) 2000-09-07 2001-09-07 How to analyze and use data from hypertensive patients

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/657,027 US6632180B1 (en) 2000-09-07 2000-09-07 Method for evaluating and treating hypertension
US09/657,027 2000-09-07
US09/860,199 US6595926B1 (en) 2000-09-07 2001-05-17 Method for evaluating and treating hypertension
US09/860,199 2001-05-17

Publications (2)

Publication Number Publication Date
WO2002019894A2 WO2002019894A2 (en) 2002-03-14
WO2002019894A3 true WO2002019894A3 (en) 2002-07-18

Family

ID=27097318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/028009 WO2002019894A2 (en) 2000-09-07 2001-09-07 Methods for analyzing and using data from hypertensive patients

Country Status (6)

Country Link
US (2) US6595926B1 (en)
EP (1) EP1322220A4 (en)
JP (1) JP2004508546A (en)
AU (2) AU8886101A (en)
CA (1) CA2421285A1 (en)
WO (1) WO2002019894A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
PL1750862T3 (en) 2004-06-04 2011-06-30 Teva Pharma Pharmaceutical composition containing irbesartan
US20060094028A1 (en) * 2004-11-04 2006-05-04 Welch Allyn, Inc. Rapid diagnostic assay
US20070009591A1 (en) * 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070135691A1 (en) * 2005-12-12 2007-06-14 General Electric Company Medicament compliance monitoring system, method, and medicament container
EP2012788A4 (en) 2006-04-18 2010-05-26 Ekr Therapeutics Inc Pre-mixed, ready-to-use iv bolus compositions and methods of use
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2020097210A1 (en) * 2018-11-06 2020-05-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Personalized treatment for cardiomyopathy and heart failure by measuring renin activity, pro-renin, pro-renin, receptor levels in blood

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080966A (en) * 1976-08-12 1978-03-28 Trustees Of The University Of Pennsylvania Automated infusion apparatus for blood pressure control and method
US4425920A (en) * 1980-10-24 1984-01-17 Purdue Research Foundation Apparatus and method for measurement and control of blood pressure
US5687731A (en) * 1992-09-10 1997-11-18 Mti, Ltd. Oscillometric method for determining hemodynamic parameters of the arterial portion of patient's circulatory system and a measuring system for its realization
US5830131A (en) * 1994-04-15 1998-11-03 Vital Insite, Inc. Apparatus and method for measuring an induced perturbation to determine a physical condition of the human arterial system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911909A (en) * 1987-01-02 1990-03-27 E. I. Du Pont De Nemours And Company Method of controlling hypertension using monoclonal antibodies to angiotensin-II
US5942548A (en) * 1991-10-29 1999-08-24 G.D. Searle & Co. Use of ethynyl alanine amino diol compounds for treatment of hypertension
US5849773A (en) * 1994-03-14 1998-12-15 G. D. Searle & Co. Amino acyl amino propargyl diol compounds for treatment of hypertension
AU6760298A (en) 1997-04-04 1998-10-30 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating hypertension
US5938626A (en) * 1998-07-24 1999-08-17 Virginia Commonwealth University Apparatus for lowering intra-abdominal pressure
US6632180B1 (en) * 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080966A (en) * 1976-08-12 1978-03-28 Trustees Of The University Of Pennsylvania Automated infusion apparatus for blood pressure control and method
US4425920A (en) * 1980-10-24 1984-01-17 Purdue Research Foundation Apparatus and method for measurement and control of blood pressure
US5687731A (en) * 1992-09-10 1997-11-18 Mti, Ltd. Oscillometric method for determining hemodynamic parameters of the arterial portion of patient's circulatory system and a measuring system for its realization
US5830131A (en) * 1994-04-15 1998-11-03 Vital Insite, Inc. Apparatus and method for measuring an induced perturbation to determine a physical condition of the human arterial system

Also Published As

Publication number Publication date
JP2004508546A (en) 2004-03-18
AU8886101A (en) 2002-03-22
US6595926B1 (en) 2003-07-22
AU2001288861B2 (en) 2007-04-26
EP1322220A4 (en) 2008-12-31
CA2421285A1 (en) 2002-03-14
US20050090752A1 (en) 2005-04-28
EP1322220A2 (en) 2003-07-02
WO2002019894A2 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
WO2003037313A3 (en) Methods for the treatment of addiction
WO2001050950A3 (en) Apparatus and methods for monitoring and modifying anticoagulation therapy of remotely located patients
TW200503653A (en) Methods for predicting an individual's clinical treatment outcome from sampling a group of patients' biological profiles
WO2006041664A3 (en) Baroreflex activation and cardiac resynchronization for heart failure treatment
WO2006041678A3 (en) Pharmaceutical treatment effectiveness analysis computer system and methods
WO2002019894A3 (en) Methods for analyzing and using data from hypertensive patients
US20110295338A1 (en) Bci apparatus for stroke rehabilitation
WO2005028029A3 (en) Patient monitoring, diagnosis, and/or therapy systems and methods
EP1541193A4 (en) Medical treatment system using biological regulation function alternate, cardiac pacing system based on the medical treatment system, blood pressure regulating system, and cardiac disease treating system
AU2002314901A1 (en) Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
WO2004028341A3 (en) Susceptibility gene for human stroke; methods of treatment
CY1107640T1 (en) METHOD FOR CERTIFICATING FACTORS FOR DIABETES TREATMENT
Gaertner et al. Block of the brachial plexus branches by the humeral route. A prospective study in 503 ambulatory patients. Proposal of a nerve‐blocking sequence
BR0206251A (en) Methods to Evaluate and Treat Leukemia
Farmahini Farahani et al. The Effect of of hand massage on anxiety and physiological indicators before surgery
NO20022916D0 (en) System and procedure for medical treatment assistance and computer program
AU2003235588A8 (en) System, method and computer program product for improving treatment of medical patients
WO2003103473A3 (en) Apparatus and method for performing a surgical procedure
WO2003087315A3 (en) Pre-and post therapy gene expression profiling to identify drug targets
WO2008136709A3 (en) Method of acupuncture and a needle for carrying out said method
WO2007117589A3 (en) Enhanced fc receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis
DE60018097D1 (en) SECURITY MECHANISM FOR PREVENTING UNINTENDED PATIENT INJECTION AND METHOD
Coulling Fundamentals of pain management in wound care
KR100435171B1 (en) Method and apparatus of SOOJI-CHIM medical treatment using handsphone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2421285

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002524383

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001968624

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001288861

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001968624

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001288861

Country of ref document: AU